Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontunisertib ADME and Absolute Bioavailability Study in Healthy Males
NCT07672574Phase 1Recruiting
- Sponsor
- Agomab Therapeutics
- Start
- Sep 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of ontunisertib in Crohn's disease (3 arms), sponsored by Agomab Therapeutics. Primary endpoints: Absolute bioavailability of ontunisertib at 8 days, Cumulative amount of total radioactivity excreted in urine and feces at 10 days and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
ontunisertib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07672574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672574.